Trial Profile
A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Ocular inflammation; Ocular pain; Postoperative inflammation; Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors KALA BIO; Kala Pharmaceuticals
- 01 Sep 2023 Last checked against ClinicalTrials.gov record.
- 18 Oct 2018 According to a Kala Pharmaceuticals media release, data from the study will be presented at the the 2018 American Academy of Ophthalmology (AAO) annual meeting.
- 23 Aug 2018 The U.S. Food and Drug Administration (FDA) has approved INVELTYSTM (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery, according to a Kala Pharmaceuticals media release.